Ping Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ping Xu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas E. Navin
Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA
99 shared publications - Yuehui Zhao
The University of Texas MD Anderson Cancer Center 2 Department of Systems Biology Houston, Texas
99 shared publications - Amado Zurita-Saavedra
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
98 shared publications - Ana M. Aparicio
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
98 shared publications - Christopher J. Logothetis
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
98 shared publications - Emi Sei
Department of Systems Biology, UT MD Anderson Cancer Center, Houston, TX, USA
98 shared publications
Latest Publications
- 9 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF25
Dual Functions of B7-H3–MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-Derived Suppressor Cells and Fibroblasts
B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3–targeting therapy. In this study, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a noncanonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs (M-MDSC) and induces cellular senescence. The senescent M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs (Gr-MDSC). Genetic deletion or pharmacologic inhibition of B7-H3/CD276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3–targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable antitumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms. Significance: Our studies uncovered a long-unknown B7-H3 signaling that orchestrates the cross-talk of cancer cells with myeloid and stromal cells in the host and provided novel mechanistic insights and effective combinatorial strategies for B7-H3–targeting immunotherapy in advanced prostate cancer among other malignancies.
- 9 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF25
Dual Functions of B7-H3–MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-Derived Suppressor Cells and Fibroblasts
B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3–targeting therapy. In this study, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a noncanonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs (M-MDSC) and induces cellular senescence. The senescent M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs (Gr-MDSC). Genetic deletion or pharmacologic inhibition of B7-H3/CD276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3–targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable antitumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms. Significance: Our studies uncovered a long-unknown B7-H3 signaling that orchestrates the cross-talk of cancer cells with myeloid and stromal cells in the host and provided novel mechanistic insights and effective combinatorial strategies for B7-H3–targeting immunotherapy in advanced prostate cancer among other malignancies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S13. Tumor subclone changes in longitudinal ctDNA samples: P182, P190, P196, P198, P203, and P204
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S13. Tumor subclone changes in longitudinal ctDNA samples: P182, P190, P196, P198, P203, and P204
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Cox proportional hazards model of the genomic aberrations and overall survival
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Cox proportional hazards model of the genomic aberrations and overall survival
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S11. Tumor subclone changes in longitudinal ctDNA samples: P126, P127, P131, P132, P138, and P142
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S11. Tumor subclone changes in longitudinal ctDNA samples: P126, P127, P131, P132, P138, and P142
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S6. Mutation signature and CNV signature changes in relation to treatments
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S6. Mutation signature and CNV signature changes in relation to treatments
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S2. Landscape of genomic aberrations in longitudinal plasma samples
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S2. Landscape of genomic aberrations in longitudinal plasma samples
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S22 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S22. Survival analysis of identified genomic alterations that related to chemotherapy resistance or shorter PFS of chemotherapy in cBioPortal
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S22 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S22. Survival analysis of identified genomic alterations that related to chemotherapy resistance or shorter PFS of chemotherapy in cBioPortal
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S8. CNV profiles of patients with MCM7 alterations
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S8. CNV profiles of patients with MCM7 alterations
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S17 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S17. Clonal substructure, evolutionary dynamics, and genomic features in relation to clinical parameters
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S17 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S17. Clonal substructure, evolutionary dynamics, and genomic features in relation to clinical parameters
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S9. Tumor subclone changes in longitudinal ctDNA samples: P27, P35, P149, P263, P77, and P151
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S9. Tumor subclone changes in longitudinal ctDNA samples: P27, P35, P149, P263, P77, and P151